NAD+ metabolism restriction boosts high-dose melphanan efficacy in multiple myeloma patients

A novel strategy to hinder the progression of multiple myeloma involves inhibiting NAD+ production. While solely targeting the NAMPT enzyme proved ineffective, the Preiss-Handler pathway, especially NAPRT1, emerged as pivotal in rescuing cancer cells. Cells lacking NAPRT1 become more susceptible to oxidative stress, and the dual targeting of NAMPT/NAPRT1 increased the efficacy of chemotherapy in multiple myelom. RNA samples extracted from tumoural CD138-positive plasmacells purified from 20 local NDMM patients were profiled for correlation analysis with clinical data